Distinct differences in immunological properties of equine orthobiologics revealed by functional and transcriptomic analysis using an activated macrophage readout system.
Authors: Pezzanite Lynn M, Chow Lyndah, Griffenhagen Gregg M, Bass Luke, Goodrich Laurie R, Impastato Renata, Dow Steven
Journal: Frontiers in veterinary science
Summary
# Editorial Summary Three widely marketed orthobiological therapies for equine orthopaedic injury—mesenchymal stromal cells (MSC), autologous conditioned serum (ACS), and platelet-rich plasma (PRP)—lack rigorous comparative data on their biological activity, leaving practitioners without clear guidance on which treatment offers superior immunomodulatory benefit for specific clinical scenarios. Pezzanite and colleagues conducted a functional and transcriptomic analysis using activated macrophages as a bioassay system to directly compare the anti-inflammatory and immunomodulatory properties of these three therapies, thereby establishing an objective framework for evaluating their relative efficacy. The study revealed distinct differences in how each orthobiologic modulates macrophage function and gene expression, with implications for understanding their respective mechanisms of action and optimal clinical applications. These findings provide the evidence base veterinarians and rehabilitation professionals need to make informed treatment selections based on biological activity rather than marketing claims alone, potentially improving outcomes in cases of soft-tissue injury, joint disease, and other orthopaedic conditions where immunomodulation plays a critical role in healing.
Read the full abstract on PubMed
Practical Takeaways
- •These three orthobiologic therapies are NOT equivalent—they have different immunomodulatory mechanisms, so selection should be based on the specific type of injury and inflammatory response you're trying to address
- •Use this comparative data to justify to clients why different orthobiologic options exist and why one might be chosen over another for their horse's particular condition
- •The transcriptomic findings provide scientific evidence to support clinical decision-making when selecting between MSC, ACS, or PRP for orthopedic cases
Key Findings
- •Three commonly used orthobiological therapies (MSC, ACS, and PRP) demonstrated distinct differences in anti-inflammatory and immunomodulatory activity when compared using activated macrophage bioassay systems
- •Functional and transcriptomic analysis revealed differential immunological properties among the three orthobiologic compounds
- •Study provides comparative biological activity data to distinguish efficacy profiles of MSC, ACS, and PRP therapies